ANI PHARMACEUTICALS INC 8-K

What Happened

• ANI Pharmaceuticals (ANIP) filed an 8-K on January 12, 2026 (Item 2.02) to announce select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, and to provide preliminary financial guidance for 2026. The company also disclosed that President & CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026.
• The filing furnished a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2). The company states the reported figures are preliminary, based on management estimates, are not comprehensive, may change (possibly materially), and have not been audited or reviewed by the independent auditor.

Key Details

• Filing date: January 12, 2026; reporting period: Q4 and fiscal year ended December 31, 2025.
• Results described are preliminary and unaudited; independent registered public accounting firm has not audited or reviewed them.
• Preliminary 2026 financial guidance was provided (details in the attached press release and investor presentation).
• CEO Nikhil Lalwani will present at the J.P. Morgan Healthcare Conference on January 13, 2026 (investor presentation attached as Exhibit 99.2).

Why It Matters

• Investors should treat these numbers as provisional: the company warns the preliminary results and guidance may change and lack audit assurance, which can materially affect final reported earnings and revenue figures.
• The investor presentation and the CEO’s JPM presentation may offer management’s explanation of results and outlook; those events are where more context and potential forward-looking detail will be available.
• Because this filing relates to earnings and forward guidance, it can influence short-term market reaction and investor expectations for ANIP, but final audited results will be more definitive.